INNV-01. PROTECT STUDY: PROPHYLACTIC SKIN TOXICITY THERAPY WITH CLINDAMYCIN AND CLOBETASOL OR SKIN BARRIER IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS

摘要

BACKGROUNDTumor treating fields (TTFields) are non-invasive, anti-mitotic low intensity, intermediate frequency (200 kHz) alternating electric fields. TTFields have demonstrated survival advantage when combined with maintenance TMZ in newly diagnosed glioblastoma. TTFields are applied continuously (>18 hours/day) using a set of four transducer arrays placed on the patients scalp. The main TTFields-related adverse event is mild-moderate dermatitis and pruritus. Strategies that mitigate skin events may improve quality of life, adherence, and prevent treatment interruptions. Several clinical trials are evaluating the concomitant use of TTFields with a variety of immunotherapies which are also associated with dermatologic toxicities. This multicenter, prospective, randomized, double-blind pilot study will test the efficacy and safety of topical clobetasol and clindamycin and a skin barrier to prevent skin events from TTFields.